Biopharma News

Several biopharmaceutical companies announce plans to launch R&D into Zika vaccine candidates.

Pfizer and Bristol-Myers Squibb enter into agreement with Portola to develop and commercialize andexanet alfa in Japan.

Novartis announced the companies plan to boost growth at Alcon, the company’s vision care division.

Amgen announces FDA will review the company’s BLA for ABP 501.

NICE announces plans to back biosimilar alternatives to Merck’s Remicade.

On Jan. 27, 2016 FDA announced it plans to review Merck’s investigational antitoxin prevention bezlotoxumab.

Baxter has voluntarily recalled lots of IV solutions due to potential container leakages and particulate matter.

Novartis announced on Jan. 5, 2016 that the company is collaborating with Qualcomm to develop cloud-based technology for COPD patients.

Samsung Bioepis receives approval from the European Commission for the Enbrel Biosimilar, Benepali.

Takeda Pharmaceutical Company and enGene have entered into a strategic alliance to develop novel therapies for specialty gastrointestinal diseases.

Adimab and Merck have entered into a definitive agreement to transfer Adimab’s antibody technology to Merck Research Laboratories.

Cell Therapy Catapult and Synpromics announced a collaboration to increase scale and efficiency of viral vector manufacturing.

Shire’s acquisition of Baxalta creates a leading company for rare disease drugs.

AstraZeneca and Moderna Therapeutics set to collaborate on mRNA therapeutic candidates for the treatment of cancer.

Novartis enters into alliance and licensing agreement with Surface Oncology.

FDA approved 45 novel new drugs in 2015, led by therapies for orphan diseases and and expedited approvals.

Takeda Pharmaceuticals announced the acquisition of a biopharmaceuticals manufacturing plant in Minnesota.

The Cell Therapy Catapult, University of Birmingham, and Cancer Research Technology collaborate on CAR-T cell immuno-oncology therapy development.

Health Canada approved AbbVie’s Humira for the treatment of adults with hidradenitis suppurativa.

Ionis Pharmaceuticals receives orphan drug designation for HTTRx for the treatment of Huntington’s disease.

Infrastructure and payer decisions will determine drug choices in emerging and developed regions.

GlaxoSmithKline acquires Bristol-Meyers Squibb’s late-stage HIV R&D assets.

This month marks the death of a pioneering, yet pragmatic, thinker whose work brought PAT and QbD to more pharmaceutical and biopharmaceutical companies around the world.

Synpromics announced collaborations with Avalanche Biotechnologies and Applied Genetic Technologies Corporation to use synthetic promoters to develop gene therapies, including adeno-associated virus technology for treating eye diseases.

The aim of the collaboration is to advance the use of Cellectar’s phospholipid drug conjugate platform for targeted delivery of a selection of Pierre Fabre’s cytotoxics.

AstraZeneca announced the completion of a tender offer for all of the outstanding ZS Pharma shares.

Through a strategic alliance with WuXi AppTec and a $50 million facility investment, AstraZeneca announces biologics and small-molecule expansion in China.

AstraZeneca partners with the Wallenberg Center for Protein Research to conduct studies on the Secretome.